Related Experiment Video
Updated: Aug 10, 2026

Glomerular Outgrowth as an Ex Vivo Assay to Analyze Pathways Involved in Parietal Epithelial Cell Activation
Published on: August 19, 2020
Treatment of focal segmental glomerulosclerosis
1Division of Nephrology and Dialysis, IRCCS, Maggiore Hospital, Milan, Italy. ponticel@polic.cilea.it
Abstract:
The prognosis of untreated patients with focal segmental glomerulosclerosis is poor, as the disease progress to end-stage renal disease in approximately 50--70% of nephrotic patients. Although focal segmental glomerulosclerosis was initially considered to be a steroid-resistant disease, several studies have shown a better responsiveness to more prolonged courses of steroids. For patients with steroid-resistant or -dependent focal segmental glomerulosclerosis, cyclosporine A and cytotoxic agents have shown efficacy in clinical trials. Plasmapheresis or LDL-apheresis may represent a rescue treatment in patients who do not respond to other therapies. The role of other agents used in focal segmental glomerulosclerosis, including azathioprine, mycophenolate mofetil, tacrolimus, pefloxacin or vitamin E is still poorly defined.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Nephrotic Syndrome II : Assessment and Medical Management
Acute Kidney Injury V: Interprofessional Care

